Last year, the American laboratory produced more than 3 billion doses of its mRNA vaccine, developed in partnership with BioNTech.
Article written by
Published
Update
Reading time : 1 min.
An objective to reach approximately 100 billion dollars (87.6 billion euros) in turnover. After having already withdrawn generous profits from its vaccine against Covid, the American laboratory Pfizer plans to sell another 32 billion dollars (28 billion euros) this year, as well as 22 billion dollars (19.2 billion euros) of its pill intended to treat the virus.
Pfizer has already sold 72 million dollars (63 billion euros) of anti-Covid pills in 2021, a treatment marketed under the name Paxlovid, authorized at the end of December in the United States and in around forty countries since. The group hopes to produce 120 million doses throughout the year.
The American laboratory has produced more than 3 billion doses of the mRNA vaccine called “Comirnaty”, developed in partnership with the German biotech BioNTech, which has already earned it 36.8 billion dollars (31.5 billion euros) in total in 2021. This vaccine has captured 70% of the market share in the United States and the European Union. Pfizer’s turnover therefore jumped 95% to 81.3 billion dollars (71 billion euros), and its net profit more than doubled to 22 billion dollars (19.2 Billions of Euro’s).
Pfizer, which planned in early 2021 to sell for only 15 billion dollars (13.1 billion euros) of its anti-Covid vaccine before raising its forecasts several times, hopes to produce 4 billion additional doses this year. The group has launched a clinical trial to test a specific version to fight against the Omicron variant. He also recently requested emergency authorization in the United States of his vaccine for children aged 6 months to 4 years, which would then become the first available for this age group.